Literature DB >> 15841463

Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats.

Ramón Bataller1, Erwin Gäbele, Christopher J Parsons, Terry Morris, Liu Yang, Robert Schoonhoven, David A Brenner, Richard A Rippe.   

Abstract

Recent evidence indicates that the renin-angiotensin system (RAS) plays a major role in liver fibrosis. Here, we investigate whether the circulatory RAS, which is frequently activated in patients with chronic liver disease, contributes to fibrosis progression. To test this hypothesis, we increased circulatory angiotensin II (Ang II) levels in rats undergoing biliary fibrosis. Saline or Ang II (25 ng/kg/h) were infused into bile duct-ligated rats for 2 weeks through a subcutaneous pump. Ang II infusion increased serum levels of Ang II and augmented bile duct ligation-induced liver injury, as assessed by elevated liver serum enzymes. Moreover, it increased the hepatic concentration of inflammatory proteins (tumor necrosis factor alpha and interleukin 1beta) and the infiltration of CD43-positive inflammatory cells. Ang II infusion also favored the development of vascular thrombosis and increased the procoagulant activity of tissue factor in the liver. Livers from bile duct-ligated rats infused with Ang II showed increased transforming growth factor beta1 content, collagen deposition, accumulation of smooth muscle alpha-actin-positive cells, and lipid peroxidation products. Moreover, Ang II infusion stimulated phosphorylation of c-Jun and p42/44 mitogen-activated protein kinase and increased proliferation of bile duct cells. In cultured rat hepatic stellate cells (HSCs), Ang II (10(-8) mol/L) increased intracellular calcium and stimulated reactive oxygen species formation, cellular proliferation and secretion of proinflammatory cytokines. Moreover, Ang II stimulated the procoagulant activity of HSCs, a newly described biological function for these cells. In conclusion, increased systemic Ang II augments hepatic fibrosis and promotes inflammation, oxidative stress, and thrombogenic events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15841463     DOI: 10.1002/hep.20665

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  54 in total

1.  Enhanced angiotensin-converting enzyme 2 attenuates angiotensin II-induced collagen production via AT1 receptor-phosphoinositide 3-kinase-Akt pathway.

Authors:  Le Bu; Shen Qu; Xiang Gao; J-J Zou; Wei Tang; L-L Sun; Z-M Liu
Journal:  Endocrine       Date:  2010-12-28       Impact factor: 3.633

Review 2.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

3.  Activation of MEK 1/2 and p42/44 MAPK by angiotensin II in hepatocyte nucleus and their potentiation by ethanol.

Authors:  Annayya R Aroor; Youn Ju Lee; Shivendra D Shukla
Journal:  Alcohol       Date:  2009-06       Impact factor: 2.405

4.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 5.  Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease.

Authors:  Jessica Wen
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

6.  Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice.

Authors:  James P Luyendyk; Glenn H Cantor; Daniel Kirchhofer; Nigel Mackman; Bryan L Copple; Ruipeng Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-29       Impact factor: 4.052

7.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

Review 8.  Renin-angiotensin system in the pathogenesis of liver fibrosis.

Authors:  Regina Maria Pereira; Robson Augusto Souza dos Santos; Filipi Leles da Costa Dias; Mauro Martins Teixeira; Ana Cristina Simões e Silva
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

9.  Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.

Authors:  Yosui Tamaki; Yukiomi Nakade; Taeko Yamauchi; Yuichi Makino; Shiro Yokohama; Mitsuyoshi Okada; Kazunobu Aso; Hiroyuki Kanamori; Tomohiko Ohashi; Ken Sato; Haruhisa Nakao; Masakazu Haneda; Masashi Yoneda
Journal:  J Gastroenterol       Date:  2012-08-14       Impact factor: 7.527

10.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.